83 results
Page 2 of 5
8-K
EX-1.1
0tidm s1x
20 Jan 22
Entry into a Material Definitive Agreement
4:55pm
8-K
EX-1.1
ltdwd6qjf1rn4cm
17 Nov 21
Apellis Pharmaceuticals Announces Pricing of Public Offering of Common Stock
9:04am
8-K
EX-10.1
tros0pxv
8 Jul 21
Entry into a Material Definitive Agreement
7:15am
8-K
EX-10.1
g699x2zn2nzseh6jabg4
7 Jan 21
Entry into a Material Definitive Agreement
7:08am
8-K
EX-99.1
feor5efyt2m3 u28i5
27 Oct 20
Sobi obtains global co-development and exclusive ex-U.S. commercialization rights for systemic pegcetacoplan, a targeted C3 therapy
7:17am
8-K
EX-10.1
6b7icnpkl
7 May 20
Apellis Pharmaceuticals Announces Private Placement of Convertible Senior Notes
7:44am
424B5
awu8eqb7w 9g4y1
9 Jan 20
Prospectus supplement for primary offering
5:25pm
8-K
EX-1.1
gs381k fmhy42yxvprw
9 Jan 20
Apellis Pharmaceuticals Announces Pricing of Public Offering of Common Stock
5:22pm